12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ALKS 9070: Phase III started

Alkermes began a double-blind, placebo-controlled Phase III trial evaluating 300 and 600 mg once-monthly intramuscular ALKS 9070 for 12 weeks in about 690 patients...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >